MYGN — Myriad Genetics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual balance sheet for Myriad Genetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	340	115	141	102	150
Net Total Accounts Receivable
Net Total Receivables	91.3	102	114	121	115
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	485	275	314	298	333
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	125	187	181	172	163
Net Goodwill
Net Intangible Assets
Long Term Investments
Other Long Term Assets
Total Assets	1,321	1,199	1,147	1,028	707
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Other Current Liabilities
Total Current Liabilities	204	137	156	164	134
Long Term Debt
Total Long Term Debt
Total Debt
Deferred Income Tax
Minority Interest
Total Other Liabilities
Total Liabilities	353	313	363	327	339
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	968	886	783	701	368
Total Liabilities & Shareholders' Equity	1,321	1,199	1,147	1,028	707
Total Common Shares Outstanding